Navigation Links
Saving Lives of Florida Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment

Tallahassee Dermatologist Encourages Regular Skin Examinations

TALLAHASSEE, Fla., Sept. 12 /PRNewswire/ -- Once every two hours a Florida resident is diagnosed with a new case of melanoma skin cancer, according to the American Cancer Society. A local dermatologist is working to decrease this alarming statistic, and increase the likelihood that local residents diagnosed with this deadliest type of skin cancer will survive.

"Staying out of the sun or protecting your skin from harmful ultraviolet rays is the best defense against skin cancer, but it's equally important to have your skin examined at least once a year by a board-certified dermatologist, especially if you have any moles that are irregular in shape or have recently appeared or changed in size, shape or color," said Dr. Armand Cognetta, medical co-director of the nationwide trial of Dermatology Associates of Tallahassee. "Early detection of suspicious moles is the key to preventing melanoma."

When melanoma is caught in its early stages, it's almost always curable.

Risk factors for melanoma include:

* Sunlight, or too much exposure to ultraviolet radiation

* Presence of many moles and/or large moles (>6mm)

* Fair skin, freckling, light eyes, or natural red or blond hair

* Family history of melanoma

* Past personal history of melanoma

Traditionally, dermatologists have relied on their own eyes and judgment in deciding whether to remove a suspicious mole.

Dermatology Associates of Tallahassee is participating in a nationwide patient trial to test an investigational medical technology called MelaFind(R), designed to assist physicians in the early diagnosis of melanoma.

MelaFind is a non-invasive hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions (moles). MelaFind then analyzes the images in order to provide information to the physician and produce a recommendation of whether the lesion should be biopsied.

"We encourage patients to come in for skin exams in general, especially during the summer months when people tend to spend a lot of time outdoors in the sun," said Dr. Cognetta.

If you think you have a mole that may be cancerous, and would like to have it examined, please contact Dermatology Associates of Tallahassee at 850-877-4134. You may also be eligible to participate in the MelaFind trial.

About Dermatology Associates of Tallahassee

Dermatology Associates of Tallahassee is proud to have served the community for over 20 years. We are your skin cancer management professionals providing examination and treatment of skin lesions and disease. We have seven dermatologists on staff, and pride our self in offering complete skin care management, Mohs micrographic surgery, Puva light therapy, and radiation treatment. Dr. Cognetta is the medical co-director of the MelaFind trial and is only one of forty directors of the American College of Mohs Micrographic Surgery fellowship. Dr. Cognetta has devoted and built his practice in skin cancer detection and treatment over the last seventeen years.

Media Contact:

Erich Sandoval, Lazar Partners

Tel: (212) 867-1762

SOURCE Dermatology Associates of Tallahassee
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. CuraGen Presents Update on Clinical Development Program for Belinostat
10. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
Post Your Comments:
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):